Stockscreener 앱 받기
2.19
3.30%
0.07
전일 마감가:
$2.12
열려 있는:
$2.14
하루 거래량:
1.06M
Relative Volume:
0.74
시가총액:
$97.10M
수익:
-
순이익/손실:
$-97.22M
주가수익비율:
-1.587
EPS:
-1.38
순현금흐름:
$-82.44M
1주 성능:
+8.96%
1개월 성능:
+45.03%
6개월 성능:
-31.99%
1년 성능:
-89.02%
1일 변동 폭
$2.1308
$2.2684
1주일 범위
$2.03
$2.2684
52주 변동 폭
$1.15
$42.20
카사바 Stock (SAVA) Company Profile
명칭
Cassava Sciences Inc
전화
512-501-2444
주소
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
SAVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.19 | 97.10M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
카사바 Stock (SAVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-26 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
| 2021-04-27 | 개시 | B. Riley Securities | Buy |
| 2021-02-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-01-10 | 재확인 | Maxim Group | Buy |
모두보기
카사바 주식(SAVA)의 최신 뉴스
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
BNP Paribas Financial Markets Buys 55,813 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
Cassava Sciences Holds 2025 Annual Meeting, Elects Directors - TipRanks
Transcript : Cassava Sciences, Inc.Shareholder/Analyst Call - marketscreener.com
Cassava Sciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationSAVA - ACCESS Newswire
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Class Action Filed Against Cassava Sciences, Inc. (SAVA)February 10, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Cassava Reports Q1 2025 Financials Results, Provides Business Update - GlobeNewswire
Cassava Sciences Shifts Focus to TSC-Related Epilepsy - TipRanks
Cassava Sciences (SAVA) Faces Financial Challenges Amid Strategic Shifts - GuruFocus
Invesco Ltd. Trims Stock Position in Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Cassava Sciences (SAVA) Appoints New SVP of Neuroscience | SAVA Stock News - GuruFocus
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC - citybiz
Investors who Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky About Pending Class ActionSAVA - ACCESS Newswire
Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
카사바 (SAVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
카사바 주식 (SAVA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
1.18 |
50,000 |
59,000 |
71,300 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.86 |
59,800 |
230,828 |
11,500 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.82 |
2,000 |
7,640 |
0 |
1.21%
1.51%
자본화:
|
볼륨(24시간):